Cellectis S.A. (CLLS:NASDAQ) closed at $1.04 on October 16, 2026, down 5.88% on the day. The stock trades 80.9% below its 52-week high of $5.45 and 1.0% above its 52-week low of $1.03. Over the past year, it lost 73.9%. Cellectis S.A. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -11.86% | -28.77% | -60.00% | -74.63% | -73.87% |
In 252 trading sessions since October 16, 2025, CLLS closed higher on 109 days (43%). Its best day was April 13, 2026 (+19.22%) and its worst was September 14, 2026 (-40.97%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 8 times.
Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants.
Find more stocks like CLLS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.